415 studies found for:    Open Studies | "Myelodysplastic Syndromes"
Show Display Options
Rank Status Study
1 Recruiting Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant
Conditions: Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndrome;   Secondary Myelodysplastic Syndrome
Interventions: Drug: Azacitidine;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Decitabine;   Drug: Idarubicin;   Other: Quality-of-Life Assessment
2 Recruiting Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Chronic Myelomonocytic Leukemia;   Previously Treated Myelodysplastic Syndrome;   Recurrent Adult Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndrome
Interventions: Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis
3 Recruiting Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   de Novo Myelodysplastic Syndromes;   Myelodysplastic Syndrome With Isolated Del(5q);   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: Sirolimus;   Drug: Azacitidine
4 Recruiting Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Conditions: Adult Acute Megakaryoblastic Leukemia;   Adult Acute Monoblastic Leukemia;   Adult Acute Monocytic Leukemia;   Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With Maturation;   Adult Acute Myeloid Leukemia With Minimal Differentiation;   Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1;   Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL;   Adult Acute Myeloid Leukemia Without Maturation;   Adult Acute Myelomonocytic Leukemia;   Adult Erythroleukemia;   Adult Pure Erythroid Leukemia;   Alkylating Agent-Related Acute Myeloid Leukemia;   de Novo Myelodysplastic Syndrome;   Previously Treated Myelodysplastic Syndrome;   Recurrent Adult Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndrome;   Untreated Adult Acute Myeloid Leukemia
Interventions: Biological: Filgrastim;   Drug: Mitoxantrone Hydrochloride;   Drug: Cladribine;   Drug: Cytarabine
5 Recruiting Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study
Condition: Myelodysplastic Syndromes
Interventions: Drug: Deferasirox;   Drug: Deferasirox placebo
6 Recruiting Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Previously Treated Myelodysplastic Syndromes;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: decitabine;   Drug: cytarabine
7 Not yet recruiting Efficacy and Safety Study of CC-486 (ORAL AZACITIDINE) in Subjects With Myelodysplastic Syndromes
Condition: Myelodysplastic Syndromes
Intervention: Drug: CC-486 (ORAL AZACITIDINE)
8 Unknown  Darbepoetin Alpha in Myelodysplastic Syndromes (MDS)
Condition: Myelodysplastic Syndromes
Intervention: Drug: Darbepoetin
9 Unknown  Study of AR-67 (DB-67) in Myelodysplastic Syndrome (MDS)
Condition: Myelodysplastic Syndrome
Intervention: Drug: AR-67 (20S)-7-t-Butyldimethylsilyl-10-hydroxycamptothecin)
10 Recruiting Study of DSP-7888 in Patients With Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Intervention: Drug: DSP-7888
11 Recruiting Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)
Conditions: Anemia;   Myelodysplastic Syndromes (MDS);   Chronic Myelomonocytic Leukemia (CMML);   Low to Intermediate-1 MDS
Intervention: Drug: Sotatercept
12 Recruiting Molecular Epidemiology of Therapy-related Acute Myeloid Leukemia/Myelodysplastic Syndrome (AML/MDS)
Conditions: Leukemia;   Myelodysplastic Syndrome
Intervention: Behavioral: Interview
13 Unknown  Bortezomib and Low Dose Cytarabine in the Treatment of High-Risk Myelodysplastic Syndromes
Condition: Myelodysplastic Syndromes
Intervention: Drug: Bortezomib
14 Unknown  5 Day Versus 7 Day Azacitidine in Lower Risk Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Intervention: Drug: Azacitidine
15 Recruiting Observational Evaluation of Infective Risk in Myelodysplastic Syndrome Patients
Condition: Myelodysplastic Syndrome
Intervention: Drug: Antibiotic and antifungal drugs
16 Unknown  Safety And Efficacy Of Azacitidine, and Lenalidomide In Higher Risk Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Intervention: Drug: 5-Azacytidine and Lenalidomide
17 Recruiting Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome
Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Chronic Myelomonocytic Leukemia;   Previously Treated Myelodysplastic Syndrome;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Ring Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts
Interventions: Procedure: Allogeneic Bone Marrow Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Radiation: Iodine I 131 Monoclonal Antibody BC8;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
18 Unknown  Treatment of Myelodysplastic Syndromes Comparing Hydralazine/Ac. Valproic and Supportive Care in Patients Not Candidates, Refractory and/or Intolerant to Intensive Chemotherapy
Condition: Myelodysplastic Syndrome
Interventions: Drug: BSC;   Drug: HIDRA/VPA
19 Unknown  Biomarkers in Patients at Risk of Developing Myelodysplastic Syndrome or Other Disorders and in Healthy Participants
Conditions: Leukemia;   Myelodysplastic Syndromes
Interventions: Genetic: DNA methylation analysis;   Genetic: RNA analysis;   Genetic: cytogenetic analysis;   Genetic: gene expression analysis;   Genetic: mutation analysis;   Genetic: polymerase chain reaction;   Genetic: protein expression analysis;   Other: laboratory biomarker analysis
20 Unknown  Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome
Conditions: Hemochromatosis;   Myelodysplastic Syndromes
Interventions: Drug: Deferasirox;   Other: Venesection

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years